← Thermo Fisher Scientific overview

Thermo Fisher Scientific vs WuXi AppTec: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Thermo Fisher Scientific Inc (TMO)

Q3 2026
▲2▼1

Thermo Fisher Q3: Strong Q2 Results and New Wins, but China and Tariffs Weigh

  • Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating estimates. Management raised full-year guidance, and the stock jumped 8.7% to $572.32 as analysts lifted targets.

    This is the main positive force that drove the stock price during the quarter.

  • New Partnerships and Product Approvals Thermo Fisher announced an ImmuPharma manufacturing partnership, received FDA clearance for the EXENT myeloma test, and formed a Mayo Clinic venture called Precure. These expand its service offerings and add potential revenue streams.

    These new business wins support future growth and investor confidence.

  • Microbiology Sale Completed Thermo Fisher completed the $1.075 billion sale of its microbiology business. The deal frees up cash for other investments but trims near-term revenue, creating a mixed impact on the stock.

    This strategic move has both positive and negative implications for the company's financials.

  • China Weakness and Tariff Uncertainty China's academic and government demand remained weak, Asia-Pacific slightly missed expectations, and tariff uncertainty lingered. HSBC cut its target to $540, a real counterweight to the recovery.

    These risks put downward pressure on the stock and limit upside potential.

August 2026
▲3▼1

Thermo Fisher's recovery broadens, but China and tariffs weigh

  • FDA clears EXENT myeloma test The FDA cleared Thermo Fisher's EXENT myeloma test, a new product for diagnosing a type of blood cancer. This opens a fresh revenue stream and shows the company's testing business can grow beyond its current lineup.

    New product approval is a fresh positive driver for future sales.

  • Mayo Clinic Precure venture and new partnerships Thermo Fisher formed a venture with Mayo Clinic called Precure and announced other new products and partnerships. These deals broaden its future revenue sources and show its services remain in demand, supporting the stock.

    New collaborations expand future revenue and are new to this period.

  • Completed $1.075B microbiology sale Thermo Fisher completed the sale of its microbiology business for $1.075 billion. This frees up cash that can be used for other investments or debt reduction, but it also removes some near-term revenue, so the effect is mixed.

    Completing a major divestiture is a new event with mixed implications.

  • China weakness and tariff risks persist China's academic and government demand remains weak, Asia-Pacific missed slightly, and tariff risks continue. HSBC cut its target to $540, highlighting these as real counterweights to the recovery.

    These are ongoing risks that cap upside and are new details this period.

Latest
▲4

Thermo Fisher's recovery broadens as new products and deals build

  • Analysts raise targets after Q2 beat After Thermo Fisher's strong Q2, Simply Wall St lifted its fair value to $631 from $591, and Morgan Stanley, Barclays, BofA and Jefferies raised targets into the $630-650 range. Higher targets pull the stock up because they signal analysts expect more profit ahead. HSBC cut to $540, a real counterweight.

    Shows the market's upgraded view of TMO's value after results, a direct price driver.

  • Microbiology sale completed for $1.075 billion Thermo Fisher finished selling its microbiology business to Astorg for about $1.075 billion in cash plus a $50 million seller note. The unit had $645 million of 2025 revenue. Cash from the sale can fund buybacks or growth areas, but it also removes revenue near term, so the effect is mixed.

    A completed major transaction that changes TMO's business mix and cash position.

  • New products and partnerships widen offerings Thermo Fisher launched the EMPAD G2 electron detector, the Gibco CHO-K1 cell-culture panel, and agreed to resell Evosep's Eno proteomics platform. It also joined a Digital CMC Consortium and expanded cancer-monitoring work. These add future sales in instruments, bioprocessing and proteomics, supporting the stock.

    Product launches and deals are the main new growth drivers this period.

  • International revenue beats, China still a risk June-quarter revenue of $11.99 billion beat expectations, with Europe and other regions ahead of forecasts, though Asia-Pacific fell slightly short. Management said China returned to growth but academic and government demand there stayed weak, and tariff risks remain. Broad recovery supports the stock, but China is a real drag.

    Shows the geographic demand picture behind TMO's revenue beat and the key risk.

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

  • Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.

    This is the core new event that reset expectations for the company's earnings power.

  • Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.

    It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.

  • FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.

    A new regulatory approval expands the product portfolio and future revenue.

  • Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.

    A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 2026
▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

  • Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.

    This is the core new event that answers why the stock is moving now.

  • Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.

    This shows the immediate market reaction and analyst validation, which are key to the price move.

  • New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.

    This is a new contract that adds to the growth story and supports the positive outlook.

Q2 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

June 2026
▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

  • AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.

    This is a major new strategic push that could drive future revenue and investor optimism.

  • Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.

    It highlights a favorable industry trend that directly benefits TMO's core business.

  • Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.

    It explains a recent negative price reaction that may still affect investor sentiment.

  • New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.

    These are concrete new business wins that can drive revenue and show competitive strength.

WuXi AppTec Co Ltd (603259.CG)

Q3 2026
▲3▼1

WuXi AppTec surges on record H1 results and court win

  • Blowout H1 2026 results Revenue jumped 38.9% to 28.9bn yuan and net profit rose 29.4% to 11.08bn yuan, topping 10bn for the first time. Management raised full-year guidance, boosting investor confidence.

    This is the primary new financial catalyst that drove the stock in Q3.

  • Strong backlog and employee plan A 66.43bn yuan backlog (+25.2%) and the integrated CRDMO model underpin future growth. A new employee plan targets 53bn yuan 2026 revenue, signaling confidence.

    These forward-looking indicators reinforce the growth narrative and support valuation.

  • Court blocks Pentagon designation A US court injunction blocked the Pentagon's 'Chinese military company' designation, easing a key overhang. This reduces the risk of US business restrictions.

    This regulatory/geopolitical relief removes a major negative overhang, directly lifting sentiment.

  • Injunction only preliminary; lawsuit continues The injunction is only preliminary, the lawsuit continues, and an adverse final ruling could hurt US business. A mid-July selloff also showed the stock's sensitivity to market sentiment.

    This is the key counterweight: legal uncertainty and market volatility remain real risks.

August 2026
▲4

WuXi AppTec: Strong H1, Bigger Dividend, Legal Shield Against US Blacklist

  • H1 profit up 29%, revenue up 39% WuXi AppTec's first-half 2026 revenue rose 38.93% to 28.9 billion yuan and net profit rose 29.43% to 11.08 billion yuan. Strong results show the core business is growing fast, which supports the stock price.

    This is the fundamental earnings driver behind the stock's value.

  • Interim dividend raised to 1.51 billion yuan The company will pay a cash dividend of 5.1 yuan per 10 shares, totaling 1.51 billion yuan, up from 1.03 billion last year. More cash returned to shareholders makes the stock more attractive, especially for income-focused investors.

    Dividend increase is a direct capital return that supports the share price.

  • US court blocks immediate blacklist impact A US court granted WuXi AppTec a preliminary injunction, shielding it from immediate harm while it challenges the Pentagon's 1260H blacklist. This removes a major near-term risk, though the final outcome is still uncertain.

    Legal relief reduces regulatory overhang that had pressured the stock.

  • Employee plan targets 53 billion yuan revenue A new employee stock ownership plan sets a 2026 revenue target of 53 billion yuan, with shares vesting only if targets are met. This aligns staff with shareholders and signals management's confidence in future growth.

    Incentive plan ties performance to revenue growth, boosting investor confidence.

Latest
▲4

WuXi AppTec: Strong H1, Bigger Dividend, Legal Shield Against US Blacklist

  • H1 profit up 29%, revenue up 39% WuXi AppTec's first-half 2026 revenue rose 38.93% to 28.9 billion yuan and net profit rose 29.43% to 11.08 billion yuan. Strong results show the core business is growing fast, which supports the stock price.

    This is the fundamental earnings driver behind the stock's value.

  • Interim dividend raised to 1.51 billion yuan The company will pay a cash dividend of 5.1 yuan per 10 shares, totaling 1.51 billion yuan, up from 1.03 billion last year. More cash returned to shareholders makes the stock more attractive, especially for income-focused investors.

    Dividend increase is a direct capital return that supports the share price.

  • US court blocks immediate blacklist impact A US court granted WuXi AppTec a preliminary injunction, shielding it from immediate harm while it challenges the Pentagon's 1260H blacklist. This removes a major near-term risk, though the final outcome is still uncertain.

    Legal relief reduces regulatory overhang that had pressured the stock.

  • Employee plan targets 53 billion yuan revenue A new employee stock ownership plan sets a 2026 revenue target of 53 billion yuan, with shares vesting only if targets are met. This aligns staff with shareholders and signals management's confidence in future growth.

    Incentive plan ties performance to revenue growth, boosting investor confidence.

July 2026
▲3▼1

WuXi AppTec Surges on Blowout H1 Results, Court Win

  • Blowout H1 2026 earnings WuXi AppTec reported H1 2026 revenue up 38.9% to 28.9bn yuan and net profit up 29.4% to 11.08bn yuan, topping 10bn for the first time. The company raised full-year guidance, and the stock hit its daily limit.

    This is the primary new event that drove the stock higher in July.

  • Strong backlog and CRDMO model A backlog of 66.43bn yuan, up 25.2%, signals future revenue growth. The CRDMO model, which integrates research, development, and manufacturing, continues to underpin the company's competitive advantage.

    This supports the growth narrative and investor confidence.

  • US court blocks Pentagon label A US court injunction blocked the Pentagon's 'Chinese military company' designation, easing client fears about doing business with WuXi. This removes a key overhang on the stock.

    This regulatory relief is a new positive catalyst for the stock.

  • Selloff and legal uncertainty A mid-July selloff saw CRO stocks limit-down and WuXi fall over 6%, showing sensitivity to market sentiment. The injunction is only preliminary; the lawsuit continues, and an adverse final ruling could still damage its US business.

    This highlights the real counterweight and risks that remain.

▲2▼1

WuXi AppTec wins injunction against Pentagon listing, sector rally continues

  • Court injunction blocks Pentagon blacklisting A US court granted WuXi AppTec a preliminary injunction, stopping the Pentagon from enforcing its 'Chinese military company' label during the lawsuit. This removes an immediate threat that could have scared off US clients and investors, lifting the stock.

    This is the key new legal development that directly reduces regulatory risk for the company.

  • Sector-wide pharma rally gains steam Since WuXi AppTec's strong interim report on August 3, the whole pharmaceutical sector has climbed, with many stocks hitting daily limit-up. Analysts say this rally may last longer than past ones, pulling WuXi AppTec higher with the group.

    Shows the broader market momentum that is lifting WuXi AppTec's price alongside peers.

  • Legal win is only temporary, final ruling pending The injunction is not a final judgment; the lawsuit continues and the Pentagon could still prevail. If the blacklisting is upheld later, it could hurt WuXi AppTec's US business and reputation, so the risk is not fully gone.

    Provides the necessary counterweight: the legal threat is paused, not resolved.

▲3▼1

WuXi AppTec surges on blowout H1 results and raised 2026 guidance

  • H1 profit tops 10bn yuan for first time, guidance raised WuXi AppTec's first-half revenue rose 38.9% to 28.9bn yuan and net profit rose 29.4% to 11.08bn yuan, beating 10bn for the first time in a half. It raised full-year 2026 revenue guidance to 58.5-60.5bn yuan from 51.3-53bn, lifting the stock to limit-up.

    This is the core new event that directly re-rated the stock and drove the sector rally.

  • Order backlog and CRDMO model underpin growth Continuing-operations backlog reached 66.43bn yuan at end-June, up 25.2% year-on-year. Analysts say the unique CRDMO model is gaining traction with more late-stage and commercial projects, and recovering global pharma R&D funding is reviving demand for outsourcing.

    It explains the durable demand behind the raised guidance, not just a one-off earnings beat.

  • Sector-wide CRO rally amplifies the move The A-share CRO sector jumped over 7% on August 7, with 15 stocks up more than 10%. Six of eight CRO firms reporting so far showed double-digit profit growth. WuXi AppTec's results and guidance are the main catalyst pulling the whole group higher.

    Shows the stock's rise is part of a broad sector re-rating, adding momentum beyond company-specific news.

  • Earlier July selloff shows sector fragility On July 17, CRO concept stocks hit limit-down and WuXi AppTec fell over 6% amid a broad A-share slump. This reminds investors that the stock remains sensitive to market-wide risk-off moves and sector sentiment swings, even with strong fundamentals.

    Provides the counterweight: the stock is not immune to broad market and sector pullbacks.